Abstract-Background: Electronic medical records (EMRs) are used in large healthcare centers to increase efficiency and accuracy of documentation. These databases may be utilized for clinical research or to describe clinical practices such as medication usage. Methods: We conducted a retrospective analysis of EMR data from a headache clinic to evaluate clinician prescription use and dosing patterns of topiramate. The study cohort comprised 4833 unique deidentified records, which were used to determine topiramate dose and persistence of treatment.
Results: Within the cohort, migraine was the most common headache diagnosis (n = 3753, 77.7%), followed by tension-type headache (n = 338, 7.0%) and cluster or trigeminal autonomic cephalalgias (n = 287, 5.9%). Physicians prescribed topiramate more often for subjects with migraine and idiopathic intracranial hypertension (IIH) (p < 0.0001) than for those with other conditions, and more often for subjects with coexisting conditions including obesity, bipolar disorder, and depression. The most common maintenance dose of topiramate was 100 mg/day;
however, approximately 15% of subjects received either less than 100 mg/day or more than 200 mg/day. More than a third of subjects were prescribed topiramate for more than 1 year, and subjects with a diagnosis of migraine were prescribed topiramate for a longer period of time than those without migraine. Conclusions: Findings from our study using EMR demonstrate that physicians use topiramate at many different doses and for many off-label indications. This analysis provided important insight into our patient populations and treatment patterns. 5 EMR studies can also help determine compliance with treatment guidelines and demonstrate cost savings. 6 The goal of this pilot study was to explore the utility of EMR as a clinical research tool through an evaluation of patient demographics, diagnoses, and topiramate use in a cohort of patients treated at a university-based headache specialty clinic.
Methods. This study was a retrospective analysis of de-identified, aggregate EMR data from the driven by clinical care. The patient identifiers are system-generated markers that maintain related records. Medical diagnoses were recoded using both the ICD-9-CM code and description.
Conditions that might influence topiramate use were examined, including diabetes, hypertension, obesity, epilepsy, anxiety, depression, bipolar disorder, tremor, and fibromyalgia.
To ascertain dose and length of time on topiramate, tables containing the medication description (product name, dose form, strength) and instructions for each patient were merged with tables of prescription quantities, refills, and associated medication order key. The type of prescription, date, and time that the prescription was written were used to remove duplicates, and all prescription reprints were deleted. When there were multiple prescriptions for the same order on the same date with different pill quantities, the latest timed orders were retained. Maintenance dose was defined as the daily dose ordered for the longest total period of time. The start date for determining total persistence of treatment was the first order date. No adjustments for multiplicity were made due to the exploratory nature of this study. Statistical analyses were done using SAS 9.1 (SAS Institute, Cary, NC).
Results. We extracted 4833 unique records with an initial visit during the study period of April 1, 2000 through June 30, 2006. Study demographics are summarized in Table 1; most patients were white, female, and married at the time of the study. Race, gender, and age were all significantly associated with a topiramate prescription order but these results were complicated by missing data. Race was a missing field for 376 patients and 122 had no listed martial status.
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Subjects with a topiramate order were on average 2.65 years younger than nonusers (mean age ± SD: 39.30 ± 12.63 vs 41.95 ± 15.99, p < 0.001).
The median number of clinic visits was six, and the mean visit number per record was eight.
Patients who received prescription orders for topiramate had a greater number of clinic visits, with a median of nine, compared with a median of three visits for those without a topiramate order (p < 0.001). Patients who received topiramate continued their care at the Jefferson Headache Center for longer than those who did not (median: 378.5 days vs 63 days; p < 0.001).
Diagnoses. Patients evaluated at the Jefferson Headache Center were found to have diagnoses in 22 different categories. Primary headaches were most common, and migraine was the most common headache type: migraine (n = 3753; 77.7%), tension-type headache (n = 338; 7.0%), and cluster or trigeminal autonomic cephalalgias (n = 287, 5.9%). Secondary headache diagnoses, either alone or in addition to a primary headache diagnosis, were common (n = 1413; 29.2%) and included cervicalgia, post-traumatic headache, idiopathic intracranial hypertension (IIH), tumor, cerebrovascular accident, or aneurysm. A total of 2443 (50.5%) patients had multiple headache diagnoses. The most common diagnosis combinations were: chronic migraine and medication overuse headache (n = 558, 11.5%), migraine without aura and chronic migraine (n = 512, 10.6%), migraine with and without aura (n = 304, 6.3%), and migraine with aura and chronic migraine (n = 285, 5.9%).
At the Jefferson Headache Clinic, most prescription orders for topiramate were for patients with a diagnosis of migraine. Physicians ordered topiramate more often for patients with a diagnosis of migraine or IIH and less often for patients with tension headache, cluster headache, or cranial neuralgias such as trigeminal neuralgia. Patients who were overweight or obese, had bipolar disorder, depression, seizures, tremors, or fibromyalgia received a prescription order for topiramate more frequently than the rest of the patient cohort (Table 2) .
Dosing. Topiramate was prescribed at doses ranging from as low as 15 mg every other day to as high as 1600 mg per day. Figure 1 shows Persistence of treatment. Persistence of topiramate treatment was similar whether computed by the period patients took topiramate, based on prescription order data or by projection from the amount of pills taken. Figure 2 shows the proportion of patients and the total time that patients took topiramate. More than one third of all patients took topiramate for more than 1 year. Of the 2192 patients who received topiramate during the study period, 2098 had at least two orders or one order and a prescription, allowing a dimension of persistence on the drug to be calculated. 
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Topiramate is approved by the United States Food and Drug Administration (FDA) for the prevention of migraine in adults, so it is not surprising that physicians at the headache center had prescribed topiramate for nearly half of the patients in the study population. Patients who were younger, female, and white were more likely to have received topiramate, probably because these patients were more likely to have a diagnosis of migraine and chronic migraine than those in the no topiramate group. Providers were more likely to prescribe topiramate during treatment for patients with more clinic visits, possibly because the headache center's physicians tend to prescribe topiramate more often for cases of refractory headache. Our EMR does not require physicians to distinguish between chronic and episodic migraine, and many patients have both a chronic and episodic diagnosis, as patients often improve or worsen with treatment. This makes it difficult to determine if different doses are needed for those with chronic migraine.
In our study, topiramate was prescribed for uses that have not been approved by the FDA, such as IIH. Recent studies have shown topiramate to be effective for IIH. 12, 13 Many patients with secondary headaches, cluster headache, and cranial neuralgias also received topiramate. Some small studies have shown that topiramate can be helpful for patients with trigeminal neuralgia 14, 15 or cluster headache. 16 Our study also indicates that topiramate was more likely to have been prescribed for patients with coexisting medical diagnoses such as depression, bipolar disorder, and obesity. This finding could be related to the fact that depression and bipolar disorder are co-morbid conditions in chronic migraine; while obesity has been implicated as a risk factor for developing chronic migraine. 17 Physicians may also have prescribed topiramate with the hope of inducing weight loss in obese patients.
The variability of the daily doses of topiramate in the study was notable. Physicians prescribed, on average, higher doses of topiramate for patients with chronic migraine or IIH. Clinical studies to date have used daily doses of 200 mg or less for migraine prevention. In a study of patients with episodic migraine, topiramate 200 mg/day was no more effective than 100 mg/day. 18 In contrast, a minority of patients seen at the Jefferson Headache Clinic received doses higher than 200 mg/day, perhaps because they metabolized the medication more efficiently, were more resistant to medication-related side effects, and/or had conditions that were less responsive to usual treatment. Other patients received daily doses less than 100 mg, often for extended periods of time. Paresthesias, a common topiramate side effect, may be bothersome to anxious patients, and may explain why they tend to be on lower doses. The study emphasizes the importance of individualizing treatment.
Headache classification and practice evolved over the specified study period, leading to an increasing tendency for physicians to enter more than one headache diagnosis into the EMR. For example, the diagnosis of transformed migraine was initially cited on the headache center's custom list as "transformed migraine with and without rebound", a combination of two distinct diagnoses. The diagnoses were eventually separated and, for the "with rebound" diagnosis segment, the nomenclature was changed to medication overuse headache to align with new diagnostic terminology. Moreover, many patients with a diagnosis of migraine received additional diagnoses, such as cervicalgia, tension headache, or cervical dystonia, to reflect these coexisting conditions and their possible contribution to the clinical presentation of the patient's migraine disorder. This practice increased as billing documentation requirements became more rigorous. One issue related to this change in documentation is that multiple diagnoses make it difficult to determine the primary reason which motivated the patient to seek treatment; EMR does not require clinicians to list the most significant illness first.
Using EMR data for the various clinical analyses provided useful information regarding patient based on data such as height and weight, so obesity in this cohort was greatly underdiagnosed due to fact that many providers did not enter the diagnosis in the EMR. Similarly, we believe that fibromyalgia, a co-morbid condition reportedly found in more than 20% of female patients with migraine, was likely underdiagnosed.
19
Formatted: Highlight
Deleted: generally
Deleted: In this study, even common fields such as race or martial status were often missing.
Deleted: , such as obesity, could be
The data in fields for medication and dosing were also often incomplete or difficult to analyze.
For example, a prescription might have had unclear directions for administration, such as "taper as directed," requiring assumptions to be made about the intended dose. Moreover, physicians may not have documented the dispensing of drug samples to patients, perhaps affecting the initial dose and persistence analyses. In addition, patients received multiple prescriptions at the same visit. For instance, a physician would prescribe a 1-month supply of medication with three refills, but the patient would subsequently request a 90-day prescription for mail order drug delivery, which led to entry of new prescription data into the EMR. Some repeat EMR order entries were obvious, but others required manual review of the EMR to determine the actual intended dose. Finally, we needed to make assumptions about patients who lapsed in their clinic treatment. Clinic policy is not to refill prescriptions without a visit within the year.
Discontinuation was assumed, but manual review revealed that some patients who stopped taking topiramate did so because their headaches improved, they were planning to become pregnant, or they did not make a clinic visit for an extended period. Some patients continued to receive topiramate from an outside provider, and others stopped the medication only to resume it later. Additionally, the study end date placed a false stop time on those who received additional prescriptions.
Another assumption was that patients took their medication as prescribed, but many patients fail to take prophylactic medication for adequate lengths of time. Based on data from pharmacy claims, more than half of patients discontinue migraine prophylactic treatment by two months.
The rate of topiramate treatment persistence at 2 months in one study was 46.4%, and the treatment persistence of other common preventatives such as amitriptyline (34.1%) and divalproex sodium (42.7%) were even lower.
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This pilot study extracted and analyzed data from the EMR system used at the Jefferson Headache Center. 
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